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Delta and mu opioid receptors (DORs and MORs) are
inhibitory G protein-coupled receptors that report-
edly cooperatively regulate the transmission of pain
messages by substance P and TRPV1-expressing
pain fibers. Using a DOReGFP reporter mouse we
now show that the DOR and MOR are, in fact, ex-
pressed by different subsets of primary afferents.
The MOR is expressed in peptidergic pain fibers,
the DOR in myelinated and nonpeptidergic afferents.
Contrary to the prevailing view, we demonstrate that
the DOR is trafficked to the cell surface under resting
conditions, independently of substance P, and inter-
nalized following activation by DOR agonists. Finally,
we show that the segregated DOR and MOR distribu-
tion is paralleled by a remarkably selective functional
contribution of the two receptors to the control of
mechanical and heat pain, respectively. These results
demonstrate that behaviorally relevant pain modali-
ties can be selectively regulated through the targeting
of distinct subsets of primary afferent pain fibers.
INTRODUCTION
The delta and mu opioid receptors (DOR and MOR) are inhibitory
G protein-coupled receptors (GPCRs) through which endoge-
nous opioids (endorphins and enkephalins) regulate a variety of
physiological functions, including pain control, emotional tone,
and reward (Kieffer and Gaveriaux-Ruff, 2002). The MOR also
mediates the pain-relieving effects of some of the most clinically
efficacious drugs. For example, the analgesia produced by
morphine is lost in mice in which the gene that encodes the
MOR is inactivated (Matthes et al., 1996; Sora et al., 1997b).
The contribution of the DOR to pain processing is much less
clear. Although some studies report that DOR-selective agonists
exert potent analgesic effects (Narita and Suzuki, 2003; Onofrio1148 Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc.and Yaksh, 1983; Porreca et al., 1987), others found that DOR
agonists are relatively weak, particularly compared to morphine
(Gallantine and Meert, 2005; Scherrer et al., 2004).
Yet another perspective is that a functional interaction
between the two receptors contributes to opioid agonist-medi-
ated pain control at the level of the spinal cord. For example, it
has been reported that genetic inactivation or pharmacological
blockade of the DOR can potentiate the pain-relieving effect of
MOR agonists (Gomes et al., 2004; Gomes et al., 2001) and
can counteract development of the tolerance that occurs with
chronic morphine treatment (Zhu et al., 1999). This apparent
negative cooperativity between the MOR and DOR may involve
a direct interaction of the two receptors, via the formation of
MOR-DOR heterodimers (Gomes et al., 2004; for review, see
Rozenfeld et al., 2007). In fact, immunohistochemical studies
demonstrated that the MOR and DOR are coexpressed in the
same subpopulation of primary afferent ‘‘pain’’ fibers (nocicep-
tors), namely in the small-diameter, peptidergic substance
P- (SP) and calcitonin gene-related peptide (CGRP)-containing
unmyelinated afferents (Arvidsson et al., 1995a; Ji et al., 1995).
As these peptidergic afferents express the heat-sensitive
TRPV1 channel (Caterina et al., 2000) it follows that both MOR
and DOR agonists would regulate heat pain sensitivity, which
is indeed what many studies have reported (Matthes et al.,
1996; Narita and Suzuki, 2003; Sora et al., 1997b).
Processing of the two GPCRs in these neurons, however, is
thought to be very different (Cahill et al., 2007; Zhang et al.,
2006). In contrast to prototypical GPCRs, such as the MOR,
the DOR is reportedly absent from the plasma membrane of
the synaptic terminal of nociceptors, under resting conditions
(Cahill et al., 2001; Gendron et al., 2006; Morinville et al., 2003;
Patwardhan et al., 2005; Walwyn et al., 2005; Zhang et al.,
1998). Rather, the DOR is transported to central terminals via
the regulated secretory pathway, which results in the DOR being
stored in the membrane of large, peptide-containing dense core
vesicles (LDCVs; Bao et al., 2003; Zhang et al., 1998). Function-
ality of the DOR only occurs when stimuli trigger exocytosis of
LDCVs, resulting in their integration into the plasma membrane
(Bao et al., 2003). This, in turn, renders the DOR accessible to
opioid ligands. Recently, Guan et al. (2005) provided insights into
the mechanism through which the DOR is sorted to LDCVs.
These authors discovered an interaction of SP with an extracel-
lular loop of the DOR that is essential for proper DOR trafficking.
When the SP-DOR interaction was disrupted, in mice in which
the gene encoding SP was inactivated (ppt-A gene), the DOR
was no longer transported to the terminals of nociceptors in
the spinal cord.
Here we show that many of the existing conclusions concern-
ing the DOR are not tenable. Using a DOReGFP reporter knockin
mouse, we provide a substantially different view of the DOR and
MOR distribution, function and relationship to the processing of
pain messages.
RESULTS
DOR Is Expressed in Myelinated and Nonpeptidergic
Unmyelinated Pain Fibers
We recently described a reporter knockin mouse in which
a functional DOReGFP fusion receptor replaces the endoge-
nous receptor (Scherrer et al., 2006). Here, we took advantage
of this mouse to address the contribution of the DOR to pain
processing. We first examined the DOReGFP distribution in
sensory neurons of dorsal root ganglia (DRG) immunostained
with an antibody against GFP (Figure 1A) and found that 17%
of sensory neurons expressed DOReGFP. Positive cells show
intense labeling of the plasma membrane and the perinuclear
region (Figure 1B) under resting conditions. Intrathecal delivery
of the DOR agonist SNC80 (i.e., directly into the CSF by lumbar
puncture) triggered a profound internalization of DOReGFPs
(Figure 1B). Based on these observations we conclude that
the subcellular distribution and trafficking of DORs are charac-
teristic of those of a prototypical GPCR, and that DORs ex-
pressed in sensory neurons can be targeted via the intrathecal
route.
Based on previous studies using antibodies against the DOR,
we expected that the DOReGFP+ DRG cell bodies would overlap
with the peptide-containing subpopulation of unmyelinated no-
ciceptors. This was not the case (Figures 1C and 1D and Table
S1). Instead, more than 61% of DOReGFP cells were of medium
to large size and expressed NF200 (Figures 1D and 1E), a neuro-
filament marker of neurons with myelinated axons. In fact, 65%
of the DOReGFP myelinated neurons coexpressed TRPV2,
a channel that is restricted to myelinated afferents (Figure 1F
and Table S1).
Strikingly, when we directly assessed the extent of colocaliza-
tion of DOReGFP with markers of peptidergic unmyelinated no-
ciceptors, SP, CGRP and the capsaicin and heat-sensitive
channel, TRPV1, we found no overlap (Figures 1G and 1H).
Rather, all small-diameter DOReGFP neurons, which represent
39% of all DOReGFP DRG cells, bound the lectin IB4 (Figure 1I)
and coexpressed the purinergic receptor, P2X3 (Figure S1), two
features of the nonpeptidergic population of unmyelinated noci-
ceptors. We found some colocalization of CGRP and DOReGFP,
predominantly in the NF200+ neurons (Figure 1J). Together, our
results indicate that DOReGFP is expressed in myelinated and
nonpeptidergic unmyelinated DRG neurons, not in peptidergic
unmyelinated nociceptors.Dissociation of DOReGFP and Substance P
Given the large literature reporting coexpression and functional
interactions of the DOR and SP, our finding that DOReGFP
almost never colocalizes with SP+ DRG neurons was completely
unexpected. Because rapid transport of the DOReGFP from the
cell body to the terminals of SP+ cells could have made detec-
tion of the DOReGFP in DRG cell bodies difficult, we next cos-
tained for SP and DOReGFP in both the central and peripheral
terminals of primary sensory neurons. As expected, we found
that SP+ terminals in the spinal cord are concentrated in the
most superficial laminae (I and outer II) of the dorsal horn (Ho¨kfelt
et al., 1977) (Figure 2A). By contrast, the DOReGFP predomi-
nates in terminals in the most inner part of lamina II, a region
defined by its large number of PKCg interneurons (Figures 2C
and 2D). That result is of particular interest as we recently
reported that the PKCg layer of interneurons, which has been
implicated in the development of injury-induced persistent pain
(Malmberg et al., 1997), receives a myelinated primary afferent
input (Neumann et al., 2008).
We also observed a less dense band of DOReGFP staining
in lamina I, but even here confocal analysis showed that the
SP+ and DOReGFP+ terminals in lamina I do not overlap
(Figure 2B). Figures 2A–2C also show that there is light, relatively
uniform DOReGFP staining throughout the gray matter (dorsal
and ventral horns), which agrees with the distribution pattern of
the DOR revealed in radioligand binding studies (Mennicken
et al., 2003, Figure S2).
In the skin, we observed a dense plexus of DOReGFP axons
that course through the dermis and epidermis, but no colocali-
zation with SP axon terminals (Figures 2E and 2F). We conclude
that there is no overlap of the DOR and SP, in either the central
or peripheral terminals of nociceptors. Finally, we show that the
segregated expression of DOR and SP is not restricted to
somatic afferent nociceptors, but is particularly apparent for
afferents that innervate viscera (Supplemental Results, Figures
2G–2I, Figure S3). Together these results not only indicate that
the DOR is not expressed in SP+ nociceptors, but also that
the DOR is largely excluded from the innervation of visceral
organs.
The DOR Is a Prototypical GPCR that Is Trafficked via
the Nonregulated Pathway, Independently of SP
Our finding that the DOR is expressed in myelinated and non-
peptidergic unmyelinated primary afferents and localized at the
cell surface under resting conditions differs greatly from the pre-
vailing view that is based on studies using anti-DOR antibodies.
We therefore reexamined the specificity of the immunoreactivity
generated with DOR antisera. The staining pattern that we ob-
tained was identical to that reported in the literature, however,
it did not change in tissues from two different mouse strains
with a deletion of the dor gene (Filliol et al., 2000; Zhu et al.,
1999) (see Supplemental Results, Figures S4 and S5). We con-
clude that this anti-DOR antibody, which is the most widely
used, does not recognize the DOR in immunohistochemical
preparations, but rather must cross-react with an as yet uniden-
tified molecule. Additionally, we have tested several other
commonly used anti-DOR antibodies, all of which equally immu-
nostain tissue from wild-type and dor null mice (Figure S6).Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc. 1149
Figure 1. DOR Is Not Expressed by Unmyelinated Peptidergic Nociceptors but Predominates in Myelinated and Nonpeptidergic
Unmyelinated Neurons of the Dorsal Root Ganglia
(A) Dorsal root ganglia (DRG) neurons from DOReGFP reporter mice immunostained with an anti-GFP antibody. 17.1% (±2.5%, n = 1236) of DRG cells express the
DOReGFP.
(B) High power image shows the localization of DOReGFPs at the cell surface under resting conditions (arrow; plasmalemma/cytoplasm fluorescence
density = 1.7 ± 0.1) and their profound internalization (plasmalemma/cytoplasm fluorescence density = 0.4 ± 0.1, n = 12/group, p < 0.001 (Student’s t test))
30 min after spinal delivery of SNC80 (10 nmoles).
(C) Size distribution of DOReGFP+ DRG neurons compared to those expressing SP, CGRP, IB4 or NF200. DOReGFP is expressed by two populations of cells,
one of small diameter (39%) and a second of large diameter (61%).
(D) Most DOReGFP+ cells coexpress NF200 (56%), indicating that they are myelinated. Small diameter, unmyelinated cells that express DOReGFP are IB4+
(36%). Very few correspond to the peptidergic subpopulation (only 2% are SP+).
(E) Large diameter DOReGFP cells are NF200+.
(F) DOReGFP and TRPV2 are often co-expressed in large diameter neurons.
(G) DOReGFP and SP do not colocalize in DRG neurons.
(H) DOReGFP and TRPV1 almost never colocalize in DRG neurons.
(I) Small DOReGFP+ neurons bind IB4 and thus belong to the nonpeptidergic subset of unmyelinated nociceptors.
(J) DOReGFP and CGRP colocalization only occurs in some large diameter neurons.
All scale bars equal 20 mm. Arrows indicate cells where costaining occurs.These new observations clearly called into question the
proposed influence of SP on trafficking of the DOR. We, there-
fore, crossed DOReGFP mice with mice in which the ppt-A
gene encoding SP has been deleted (Cao et al., 1998). We
confirm that the staining obtained with the anti-DOR antibody is
lost in the spinal cord of ppt-A null mice (Figures 3A and 3B) but1150 Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc.further show that the loss of staining also occurs in the DRG
(Figure S7A), despite persistence of dor transcript (Figure S7B).
On the other hand, we found no change in the DOReGFP signal
in the spinal cord (Figures 3C and 3D). We also used radioligand
binding on spinal cord sections to examine independently the
distribution of the DOR in the ppt-A null mice. Figures 3E–3H
show that the pattern of DOR binding in the spinal cord is
unchanged in the ppt-A null mice, consistent with the lack of
change in the DOReGFP mice. Finally, high power confocal
imaging revealed that DOReGFP is not only present at the plasma
membrane in DRG neurons in ppt-A null mice (Figure S7D) but
has the same location in the very rare DRG neurons that coex-
press DOReGFP and substance P (Figure S7C). Taken together,
we conclude that transport of the DOR from DRG cell bodies to
their central terminals occurs independently of SP. We propose
that the DOR behaves as a prototypical GPCR that is continu-
ously trafficked to the terminals and present at the cell surface
in the resting state, where it can be activated and internalized
by agonists, a hallmark of GPCRs.
Segregation of the DOR and the MOR in Nociceptors
As our new results bear directly on others that have implicated
interactions of the DOR and MOR in the regulation of pain, we
reexamined the relationship of the DOR and the MOR in primary
afferents, by staining tissues from the DOReGFP mouse with an
antiserum directed against the MOR. The specificity of this anti-
MOR antibody is demonstrated by the loss of immunostaining in
tissues from mor null mice (Figure S8). We found an almost
complete segregation of the expression of the two opioid recep-
tors in DRG neurons (Figure 4C) and in the spinal cord
(Figure S9). Most importantly and in distinct contrast with the
pattern of DOReGFP expression, the MOR is concentrated in
the SP+ and TRPV1+ unmyelinated peptidergic nociceptors
(Figures 4A and 4B). In fact, less than 5% of DOReGFP+ and/
or MOR+ cells coexpress the two receptors. Interestingly, these
rare neurons, in which the two receptors could dimerize, were
mostly myelinated (NF200+) and of large diameter (Figure 4C).
Consistent with its expression pattern in DRG neurons, MOR
staining in the spinal cord is restricted to laminae I and IIo,
where it partially colocalizes with SP and TRPV1 (Figures 4D
and 4E).
To delve further into the association of DOR and MOR with
TRPV1 afferents, we used lumbar puncture to make an intra-
thecal injection of the TRPV1-binding neurotoxin, capsaicin,
which selectively destroys all central terminals of DRG neurons
that express TRPV1 (Figures 4G and 4H). As predicted, we found
a significant decrease of MOR staining in lamina I of the spinal
cord (Figures 4I and 4J). There was residual MOR staining in
the spinal cord, likely arising from the large number of MOR+
postsynaptic neurons (Aicher et al., 2000b; Arvidsson et al.,
1995b; Trafton et al., 2000). By contrast, when we made intra-
thecal capsaicin injections in the DOReGFP mice, there was no
decrease of DOReGFP in the spinal cord dorsal horn (Figures
4F, 4K and 4L), confirming that the MOR, but not the DOR, is
expressed in TRPV1+, unmyelinated peptidergic afferents.
Based on these experiments, we conclude that the MOR and
DOR are differentially distributed in primary sensory neurons.
The MOR is concentrated in peptidergic nociceptors; the DOR
predominates in myelinated and nonpeptidergic unmyelinated
primary afferents.
Figure 2. DOR and Substance P Do Not
Colocalize in the Central or Peripheral Ter-
minals of Sensory Neurons
(A) SP and DOReGFP+ terminals are located in
different laminae of the superficial dorsal horn
(I-IIo: laminae I and outer II).
(B) High power image of (A) shows the lack of
colocalization of DOReGFP and SP in laminae I
and outer II.
(C) DOReGFP signal is concentrated in the inner
part of lamina II (IIi), a region that contains many
PKCg+ interneurons.
(D) High power image of (C).
(E) Double immunolabeling of the glabrous skin
illustrates the dense innervation of the epidermis
(e) and dermis (d) by DOReGFP+ fibers and the
absence of colocalization with SP+ terminals.
(F) High power image shows that DOReGFP and
SP fibers are distinct, but intertwined in the dermis
of the glabrous skin.
(G) Many neurons of the nodose ganglion, which
contains the cell bodies of visceral (vagal) affer-
ents, are SP+, but almost none are DOReGFP+.
(H) There is intense SP staining in the nucleus of
the solitary tract (NTS), which is the major medul-
lary target of visceral afferents. By contrast, the
NTS is devoid of DOReGFP.
(I) The bladder contains a dense innervation by
SP+ terminals, but there is an almost complete
absence of DOReGFP. Quantitative analysis
indicated a mean of 34.4 ± 3.4 substance P
positive fibers/mm versus 2.9 ± 0.7 DOReGFP
positive fibers/mm, n = 8/group, p < 0.001
(Student’s t test).Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc. 1151
MOR and DOR Differentially Regulate Heat
and Mechanical Pain
As described above, previous studies reported comparable
effects of MOR and DOR agonists in tests of pain sensitivity.
Indeed, the great majority found that MOR and DOR agonists
reduce heat pain (Matthes et al., 1996; Narita and Suzuki,
2003; Sora et al., 1997b). Given our new observations concern-
ing the differential expression of the DOR and the MOR in heat-
sensitive peptidergic TRPV1+ nociceptors we hypothesized that
a functional correlate of this remarkable segregation might exist.
In part, this hypothesis is based on the fact that many myelinated
afferents are mechanosensitive (Cain et al., 2001; Koltzenburg
et al., 1997), suggesting that they may contribute more to
mechanical than to heat sensibility (Sun et al., 2001). To address
this question, we compared the analgesic profile of the DOR
selective agonist SNC80 to that of DAMGO, a full and selective
agonist, with nanomolar affinity, for the MOR (Zadina et al.,
1997). We tested the effect of intrathecal injections of low doses
of DAMGO or SNC80 on heat and mechanical pain in mice.
Consistent with the expression of the MOR in TRPV1-afferents,
we found that DAMGO dose-dependently reduced heat pain
responsiveness (Figure 5A). However, Figure 5B also shows
Figure 3. The DOR Is Transported to the Central
Terminals of Sensory Neurons in the Spinal Cord,
Independently of Substance P
(A) Immunoreactivity obtained with the anti-DOR antibody
is lost in mice with a deletion of the ppt-A gene.
(B) Quantification of results in (A).
(C) DOReGFP in the spinal cord is not altered in ppt-A null
mice, indicating that DOR transport from the cell body to
the central terminals of sensory neurons is independent
of SP.
(D) Quantification of results in (C).
(E and G) The binding pattern obtained with the DOR
selective ligands, [125I]-DPDPE (E) and [125I]-deltorphin II
(G), is not altered in ppt-A null mice.
(F and H) Quantification of results in E, G.
Results are expressed as mean ± SEM, n = 8/group,
*** p < 0.001.
that the same doses of DAMGO were without
significant effect against mechanical pain.
The profile of SNC80 was completely com-
plementary to that of DAMGO, under the same
experimental conditions (Figures 5D and 5E).
Thus, SNC80 dose-dependently increased
mechanical pain thresholds (Figure 5D), but
was ineffective against heat pain (Figure 5E).
The analgesic action of SNC80 against mechan-
ical pain, but not that of DAMGO against heat
pain (Figure 5C), was blocked by coadminis-
tration of a low dose of the DOR selective
antagonist naltrindole (Portoghese et al., 1990;
Figure 5F), indicating that the DOR mediates
the SNC80 analgesia. Because intrathecal
administration of analgesic doses of SNC80 in
DOReGFP mice also produced a profound inter-
nalization of the receptor in vivo, SNC80 likely
exerts its analgesic effect via an action on DRG neurons that
express the DOR (Figure 1B).
Together, these results indicate that there is not only a differen-
tial localization of the DOR and MOR in DRG cells, but also that
these differences underlie qualitatively distinct pain relieving
profiles. We suggest that the reports of DOR agonist-mediated
regulation of heat pain were generated at agonist doses that
interacted with the MOR. We conclude that spinal administration
of DOR agonists produces a selective reduction of mechanical
pain via an action at myelinated nociceptors that respond to
noxious mechanical stimuli and perhaps on mechanosensitive
nonpeptidergic afferents (including the subset that expresses
the Mrgprd; Cavanaugh et al., 2009).
DOR-Mediated Mechanical Analgesia Does Not Require
TRPV1+ Nociceptors
Given that the MOR, but not the DOR, is expressed by TRPV1+
nociceptors, we next assayed for mechanical and heat pain
responsiveness and for the analgesic effect of SNC80 in mice
in which the central terminals of TRPV1+ nociceptors were
destroyed by prior intrathecal administration of capsaicin. We
found that heat, but not mechanical pain responsiveness was1152 Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc.
Figure 4. MOR, but Not DOR, Is Expressed by TRPV1+ Peptidergic Nociceptors
(A) Almost all DRG cells that express SP coexpress the MOR.
(B) MOR is expressed in almost all TRPV1+ nociceptors, in distinct contrast with the DOR (Figure 1).
(C) Less than 5% (4.8 ± 0.7%, n = 1180) of the opioid receptor-expressing DRG cells coexpress the DOR and MOR.
(D) There is significant colocalization of MOR and SP in lamina I of the spinal cord. MOR staining extends ventrally to lamina II where SP and TRPV1 (E) are absent.
(E) MOR and TRPV1 staining colocalize in the superficial dorsal horn.
(F) DOReGFP and TRPV1 staining predominate in different laminae of the spinal cord.
(G) Intrathecal injection of a high dose of the TRPV1 agonist, capsaicin, destroys the central terminals of TRPV1+ nociceptors and eliminates TRPV1 staining in the
spinal cord.
(H) Quantification of results in (G).
(I) Reduction of MOR staining after intrathecal capsaicin (compare with B).
(J) Quantification of results in (I).
(K) Intrathecal administration of capsaicin does not alter DOReGFP.
(L) Quantification of results in (H).
Results are expressed as mean ± SEM, n = 8/group, ** p < 0.01, *** p < 0.001.abolished (Figure 5G), confirming our recent report that TRPV1+
nociceptors are absolutely required for normal heat pain sensi-
bility (Cavanaugh et al., 2009). In this respect, deletion of the
central terminals of the TRPV1+ nociceptors is functionally equi-
valent to the action of MOR agonists on these nociceptors: both
treatments produce a selective reduction of heat pain. However,
the potency of SNC80 against mechanical pain was not altered
by loss of the TRPV1+ nociceptors (Figure 5H). Based on these
results, we conclude that SNC80-mediated reduction of
mechanical pain does not require TRPV1+ nociceptors and that
the lack of expression of the DOR in these afferents accounts
for the inability of intrathecal DOR agonists to regulate heat pain.DORs Control Tissue and Nerve Injury-Induced
Mechanical Hypersensitivity
How general is the utility of DOR agonists against mechanical
pain? As treating mechanical hypersensitivity represents one of
the major current clinical challenges, we next asked whether
an action at the DOR can regulate the mechanical hypersensi-
tivity produced in two different models of chronic pain (inflamma-
tory and neuropathic). To model the inflammatory pain induced
by tissue injury, we injected complete Freund’s adjuvant (CFA)
into the hindpaw of the mouse. To model neuropathic pain, we
used the spared nerve injury model, in which two of the three
branches of the sciatic nerve are transected, resulting in aCell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc. 1153
prolonged mechanical hypersensitivity of the partially dener-
vated hind paw (Shields et al., 2003).
Four days after the CFA injection, the mice displayed both
mechanical (Figure 6A) and heat (Figure 6B) hypersensitivity,
as well as paw edema (Figure 6C). Comparable to its effect
on acute mechanical pain, intrathecal SNC80 significantly
decreased the mechanical hypersensitivity (Figure 6A) but was
without effect on the hypersensitivity to heat (Figure 6B) and
did not reduce paw edema (Figure 6C).
In the neuropathic pain model, the mice showed a profound
reduction of the mechanical withdrawal threshold of the partially
Figure 5. The DOR Agonist SNC80 Reduces Acute Mechanical, but
Not Heat Pain
(A) DAMGO dose-dependently increases tail withdrawal latency to noxious
heat.
(B) DAMGO does not significantly alter the mechanical pain threshold at doses
that are analgesic for heat pain.
(C) The analgesic effect of DAMGO in the heat pain test is not affected by the
selective DOR antagonist, naltrindole (NTI).
(D) SNC80 dose-dependently increases mechanical pain threshold.
(E) SNC80 is not effective against heat pain, at doses that are analgesic against
mechanical pain.
(F) Low doses of naltrindole (NTI) reverse the analgesic activity of SNC80,
indicating that DORs are targeted by SNC80 in vivo.
(G) Intrathecal administration of capsaicin does not change the mechanical
threshold of mice but results in a dramatic reduction of heat pain responsive-
ness.
(H) The analgesic effect of SNC80 on mechanical pain is independent of
TRPV1+, peptidergic nociceptors; it is not affected by intrathecal injection of
capsaicin.
For all experiments, the dose of naltrindole was 0.2 nmoles. Results are
expressed as mean ±SEM, n = 8-12/group, * p < 0.05, ** p < 0.01, *** p < 0.001.1154 Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc.denervated hindpaw (Figure 6D), and as generally reported for
this model, no hypersensitivity to heat (data not shown). Similar
to its effects in the inflammatory pain model, intrathecal SNC80
significantly decreased the mechanical hypersensitivity produced
by nerve injury (Figure 6D). In both models of persistent pain, the
SNC80 effect was transient; the mechanical hypersensitivity was
restored after 24 h (Figures 6A and 6D). Confirming that these
effects were mediated via an action at the DOR, we found that
a low dose of the DOR antagonist naltrindole blocked the anal-
gesic effect of SNC80 against mechanical hypersensitivity
(Figures 6E and 6F). Together, these results suggest that DOR+
mechanoreceptive DRG neurons can be selectively targeted, so
as to control both acute mechanical pain and the prolonged
mechanicalhypersensitivity thatoccurs after tissue ornerve injury.
Substance P, Rather than the DOR, Is a Major
Contributor to the Development of Tolerance
to the Analgesic Effect of Morphine
As noted above, several studies reported that tolerance to the
analgesic action of MOR agonists can be regulated by an action
at the DOR (Zhang et al., 2006; Zhu et al., 1999). Specifically,
presence of the DOR in the central terminals of nociceptors in
the spinal cord is considered critical to the development of
morphine tolerance. Because ppt-A null mice do not develop
analgesic tolerance to morphine, Guan et al. (2005) concluded
that disruption of the transport of the DOR to the central termi-
nals of SP+ unmyelinated nociceptors was the causal factor.
As we find that DOR trafficking to central terminals is, in fact,
intact in the DOReGFP mice crossed with ppt-A null mice, our
next studies dissociated the functional contribution of the DOR
and SP.
Here we reexamined the impact of deleting the ppt-A or the
dor gene on the development of morphine tolerance (Supple-
mentary results, Figures 6G–6I). In agreement with Guan et al.
(2005), we found that morphine tolerance was decreased in
ppt-A null mice, however, contrary to the literature (Zhu et al.,
1999), tolerance developed normally in dor null mice. It follows
that regulation of the MOR in pain processing is not a primary
function of the DOR. The two receptors are differentially distri-
buted in primary afferent pain fibers and selectively regulate
different pain modalities. We conclude that an interaction of
the two receptors is not required for the development of anal-
gesic tolerance with chronic morphine.
DISCUSSION
Morphine and other MOR agonists remain the drugs of choice for
the treatment of severe pain, despite the fact they have signifi-
cant adverse side effects and limited efficacy against the
mechanical hypersensitivity that occurs postoperatively or after
nerve injury (neuropathic pain). Using a DOReGFP mouse, we
now provide a reappraisal of the distribution and functional rele-
vance to pain processing of the DOR and a mechanistic rationale
for the development of novel therapeutics for chronic pain.
DOR-Mediated Control of Heat and Mechanical Pain
The MOR and DOR are highly homologous proteins, with 64%
amino acid identity (Lacoste and Evans, 2003). Many of the
Figure 6. SNC80 Significantly ReducesMechanical Hypersensitivity inModels of Inflammatory and Neuropathic Pain, without Affecting Heat
Hyperalgesia
(A) A single intrathecal injection of SNC80 reverses the mechanical hypersensitivity observed 4 days after intraplantar injection of complete Freund’s adjuvant
(CFA).
(B) SNC80 does not reduce the heat hyperalgesia produced by CFA.
(C) SNC80 did not reduce the edema generated by CFA.
(D) Intrathecal injection of SNC80 reduces the mechanical hypersensitivity induced in the spared nerve injury (SNI) model of neuropathic pain. Animals were
tested 7 days after the nerve transection.
(E) The analgesic effect of SNC80 in the CFA model of inflammatory pain is abolished by co-administration of the DOR selective antagonist, naltrindole (NTI).
(F) Naltrindole blocks the analgesic effect of SNC80 in the SNI model of neuropathic pain.
(G and H) The development of analgesic tolerance to chronic morphine is significantly reduced in ppt-A null mice, both on C57Bl6 (p < 0.001) (G) or doregfp
(p < 0.01) (H) genetic backgrounds.
(I) Tolerance to the analgesic effect of morphine develops normally in dor null mice, indicating that SP, but not the DOR, is critical to the development of morphine
tolerance.
For all experiments the doses of SNC80 and naltrindole were 10 nmoles and 0.2 nmoles, respectively. Results are expressed as mean ± SEM, n = 9-14/group,
* p < 0.05.shared amino acids are distributed among the transmembrane
domains that form the binding pocket of the receptors. As a result,
DOR agonists, including the widely used DPDPE (Mosberg et al.,
1983) and deltorphin (Erspamer et al., 1989) offer only modest
selectivity for the DOR compared to the MOR, and can activate
the MOR at high doses. Furthermore, because of the very high
intrinsic efficacy of the MOR in blocking the transmission of
pain messages at the level of the nociceptor (Jessell and Iversen,
1977; Taddese et al., 1995), cross-reactivity in in vivo studies is
particularly difficult to avoid and its extent difficult to estimate.There is, in fact, considerable evidence that DOR agonists can
block heat pain via an action at the MOR. For example, several
groups reported either a decrease or a total loss of the activity
of DOR agonists in tests of heat pain in mor null mice (Gendron
et al., 2007; Matthes et al., 1996; Scherrer et al., 2004; Sora
et al., 1997a). Other studies found that the activity of DOR agonists
against heat pain is only partially reduced, or even preserved in
DOR null mice (Scherrer et al., 2004; Zhu et al., 1999). To some
authors these data are not explained by cross-reactivity of DOR
agonists with the MOR, but rather support the idea that presenceCell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc. 1155
of the MOR is required for DOR agonists to have full activity.
Indeed, a functional interaction between the two receptors,
including dimerization, which is readily demonstrated in heterolo-
gous expression systems, is presumed to occur in SP+ nocicep-
tors (Rozenfeld et al., 2007). Given our new finding that the MOR
and DOR do not cooccur in these neurons, we suggest that cross
reactivity of DOR agonists at the MOR, rather than loss of cooper-
ativity, is the most likely explanation for the decreased activity of
DOR agonists in the MOR null mice.
To differentiate between the contribution of the DOR and the
MOR to pain processing, we delivered low doses of SNC80 (at
least 10 times lower than what is typically used) or DAMGO,
directly to the spinal cord, and then gradually increased these
doses until we reached a maximal analgesic effect, either in
the heat or mechanical pain tests. We found that intrathecal
SNC80 dose-dependently increased the mechanical pain
threshold, with no change in the response to noxious heat. The
mechanical hypersensitivity that occurs in models of inflamma-
tory and neuropathic pain was also blocked by SNC80, but the
heat hypersensitivity was not. These behavioral results correlate
well with the predominant expression of the DOR in myelinated
primary afferents and TRPV1-negative nociceptors and its
absence from heat-sensitive, TRPV1+ nociceptors.
As even these low doses of DOR agonist produced a massive
internalization of the receptor in DRG neurons, we are confident
that the pain-relieving effects occur at doses that induce activity
at the DOR. We also showed that a low dose of the high affinity
and selective DOR antagonist, naltrindole, completely blocked
SNC80-induced analgesia in the mechanical pain test. At the
same dose, naltrindole did not alter the effect of the MOR
agonist, DAMGO, in tests of heat pain, demonstrating both
that selective activity at the DOR and MOR can be achieved
and that these distinct opioid receptor subtypes regulate two
very different modalities of pain. We, of course, recognize the
possibility that systemic or intracerebral administration of DOR
agonists could exert antinociceptive effects on heat pain via an
action at supraspinal sites (Fraser et al., 2000; Hurley and Ham-
mond, 2000; Ossipov et al., 1995; Scherrer et al., 2004).
DOR Is a Prototypical GPCR
In the DOReGFP mice, the GFP is covalently bound to DOR
through a knockin strategy that left the 30 and 50 regulatory
sequences intact. In fact, the DOReGFP distribution patterns in
brain (Goody et al., 2002) and spinal cord (Mennicken et al.,
2003) are identical to those revealed in autoradiographic binding
studies using DOR ligands. This result not only indicates that
DOReGFPs are expressed in cells that endogenously express
the DOR in wild-type mice, but also that DOReGFPs are properly
trafficked to subcellular domains.
Our results raise significant questions concerning two of the
major conclusions derived from studies using antisera directed
against the DOR, namely that DOR immunoreactivity is concen-
trated in the SP-containing LDCVs of the nociceptors rather than
on the plasma membrane (Bao et al., 2003; Cahill et al., 2001; Gen-
dron et al., 2006; Morinville et al., 2003; Zhang et al., 1998) and
second thatDOR staining is lost in the central terminals ofnocicep-
tors in the spinal cord of mice with a deletion of the ppt-A gene
(Guan et al., 2005). Most importantly, the elegant cell biological1156 Cell 137, 1148–1159, June 12, 2009 ª2009 Elsevier Inc.illustration of an interaction between a G protein coupled receptor
and a peptide neurotransmitter, even if readily demonstrated in
heterologous expression systems with tagged DORs, is clearly
untenable if the two molecules do not co-occur in the SP+
neurons. For the same reason, our results cannot support the
view that DORs decrease heat pain more efficiently in the setting
of tissue injury because there is enhanced translocation of the
receptor from the LDCVs to the plasma membrane of the central
terminals of unmyelinated peptidergic receptors (Cahill et al.,
2007, 2001). Indeed, not only did we find that the DOR is absent
from SP+ and TRPV1+ nociceptors, which agrees with earlier
in situ hybridization and ligand binding studies performed in rats
and primates (Minami et al., 1995), but we also showed that func-
tional DORs are located at the plasma membrane of unmyelinated
nonpeptidergic or myelinated nociceptors, in the resting state,
where they can be activated by SNC80 to reduce mechanical pain.
Our findings also do not support the hypothesis that loss of
morphine tolerance in ppt-A null mice results from the absence
of the DOR in the SP+ nociceptor terminals (Guan et al., 2005).
Indeed, because a SP receptor antagonist can prevent the
development of morphine tolerance (Powell et al., 2003), it
appears that absence of SP alone is sufficient to explain the
phenotype of the ppt-A null mice. Whether the protein recog-
nized by the traditional DOR antibodies contributes to these
processes remains to be determined.
Specificity in the Processing and Regulation
of Pain Messages
There are two diametrically opposed views as to how noxious
stimuli evoke qualitatively distinct pain sensations. One view
holds that a particular subset of nociceptors generates a parti-
cular modality of pain, e.g., heat versus mechanical, despite
the fact that nociceptors are polymodal, i.e., respond to multiple
pain stimuli. This is the labeled line hypothesis. Another view
holds that circuits within the CNS interpret activity generated
by polymodal nociceptors, i.e., there is no peripheral specificity
in the processing of pain messages. In agreement with recent
studies (Abrahamsen et al., 2008; Cavanaugh et al., 2009), our
results indicate that at least at the level of the peripheral afferent,
there is behaviorally relevant specificity, despite the polymodal
nature of the nociceptors, and that selective regulation of
mechanical versus heat pain can be produced by interfering
with the activity of subsets of nociceptors. Figure 7 schematizes
the differential contribution of subpopulations of nociceptors to
heat and mechanical pain as well as the selective MOR- and
DOR-mediated controls that can be exerted upon these noci-
ceptors. Heat pain behavior is produced by activity of the
TRPV1+ population of nociceptors and can be blocked by
MOR selective agonists. By contrast, mechanical pain is gener-
ated by activity in different populations (myelinated and unmy-
elinated nonpeptidergic nociceptors) and can be selectively
blocked by DOR agonists. Of course, high doses of MOR
agonists could reduce mechanical pain, possibly through a direct
action on the MOR that is expressed in some mechano-sensitive
pain fibers (such as the rare afferents in which there is coexpres-
sion of the MOR and DOR), or through a cross-reactivity at the
DOR. Unfortunately, the use of such doses also triggers unac-
ceptable MOR-mediated adverse side effects, many of which
Figure 7. The Differential Expression of the DOR and MOR in Primary Sensory Neurons Allows for the Selective Pharmacological Control
of Distinct Pain Modalities
The MOR is expressed by heat-sensitive (TRPV1+), peptidergic (SP+ and CGRP+) unmyelinated nociceptors that innervate the skin (peripheral terminals; red
box). The DOR, in contrast, predominates in the mechanosensitive myelinated and nonpeptidergic unmyelinated nociceptors. The MOR+ and DOR+ sensory
neurons project to different laminae of the spinal cord (laminae I and outer II (I-IIo) and I and inner II (IIi), respectively), where they activate neurons that transmit
painful heat and mechanical messages to the brain. Because of the segregated opioid receptor expression in nociceptors, MOR agonists preferentially reduce
heat pain, while DOR agonists can relieve mechanical pain.
The MOR, but not the DOR, is also expressed in a subpopulation of sensory neurons that innervate the heart, lungs and abdominal viscera (green box). The cell
bodies of these afferents are located in the DRG or in the nodose ganglia and project to the spinal cord (visceral pain) or to the nucleus of the solitary tract (NTS) in
the brainstem (yellow box), respectively. Thus, only MOR agonists will generate visceral organ adverse side effects.involve visceral organ dysfunction (Aicher et al., 2000a). It is thus
particularly significant that we find that the DOR, in contrast to
the MOR, is largely excluded from visceral sensory afferents
(See Figure 7). It follows that peripherally restricted DOR
agonists might be useful in order to avoid their supraspinally
mediated locomotor and convulsive side effects (Jutkiewicz
et al., 2004). Finally, because we now have a tool to identify
sensory neurons with mechanoreceptive properties, our results
point to the use of the DOReGFP mouse to define the molecular
make-up of these neurons, including identification of the as yet
elusive mechanical pain transducer, which is a likely to be a valu-
able therapeutic target.
EXPERIMENTAL PROCEDURES
Immunohistochemistry
In these experiments we used standard procedures as described previously
(Neumann et al., 2008). Briefly, we incubated sections of formalin-fixed DRG
(20 mm), spinal cord or brain (40 mm) in primary antibody solution overnight
at 4C. Tissues were then placed in fluorescent-tagged secondary antibody
solution for 2 hr at room temperature. A detailed protocol and list of antibodies
used can be found in Supplemental Data.
Autoradiography
Sixteen mm frozen spinal cord sections were incubated in 40 pM [125I]-deltor-
phin II or [125I]-DPDPE and autoradiography was performed subsequently as
described (Mennicken et al., 2003). See Supplemental Data for details.Behavioral Analysis
Behavioral testing was performed in adult, male C57Bl6 mice (20–30 g; Charles
River, Hollister, CA, USA) after a week of acclimation to the housing facility.
Detailed procedures for intrathecal injections and pain testing can be found
in the Supplemental Data. To assess heat pain we measured the latency (sec)
to tail withdrawal from 55C water. For mechanical pain, we determined the
withdrawal threshold (g) of the hindpaw when stimulating the plantar surface
with calibrated von Frey hairs. All animal experiments were approved by the
Institutional Animal Care and Use Committee at UCSF and were conducted
in accordance with the NIH Guide for the Care and use of Laboratory animals.
Statistical Analysis
Analysis was performed with StatView software using the Student’s t test for
paired comparisons, or ANOVA for multiple comparisons followed by a Fisher
post hoc test. When mice were tested at different time points we used
a repeated-measures ANOVA. Differences between groups at each time point
were analyzed with a Fisher post-hoc test. All results are expressed as mean ±
SEM.
SUPPLEMENTAL DATA
Supplemental Data include eight figures, Supplemental Results, Supplemental
Experimental Procedures, and Supplemental References and can be found with
this article online at http://www.cell.com/supplemental/S0092-8674(09)00444-9.
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